Profile Image

Staff Profile

Edit

Career Summary

Biography

Dr Skelding is an early career researcher, who was appointed to a full-time continuing lecturing position at the start of 2012.  Her research focuses on understanding cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics. If these processes can be better understood, new targeted anti-cancer therapies can be discovered.  Dr Skelding's PhD investigated the use of oncolytic viruses as novel anti-cancer agents, and was funded by a National Breast Cancer Foundation (NBCF) Scholarship, as well as the commercial company, Viralytics Ltd. During her PhD, Dr Skelding developed new clinically relevant mouse models of spontaneously metastasising breast cancer, which allowed her to examine the pre-clinical effectiveness of novel viral therapies for cancer, both as single agents, and in combination with currently approved chemotherapeutic agents. Additionally, the research undertaken throughout Dr Skelding's PhD has led to the commencement of a Phase II clinical trial in the use of this virus (CAVATAK) as an intravenous treatment for melanoma, breast, and prostate cancer. In her post-doctoral studies, Dr Skelding further applied her background in cell biology to examine signal transduction pathways and the role of targeting in regulating CaMKII (calcium/calmodulin-stimulated protein kinase II) function in neuronal cells.

Since completing her post-doctoral studies in 2012, she has established her own research group that focuses on better understanding cell signalling in cancer, with a view to developing new therapies that are cancer cell-specific and suitable for the treatment of a range of cancers, with a focus on leukaemias (specifically acute myeloid leukaemia, and childhood acute lymphoblastic leukaemia).  Dr Skelding has received several awards throughout her research career, including the International Society for Neurochemistry Travel Award (2011), Best Early Career Researcher Speaker at the Hunter Medical Research Institute Cancer Research Program Symposium (2010), Best Speaker at the University of Newcastle Graduate Student’s Day (2006), University Medal in Biomedical Science (2003), the University of Newcastle Vice Chancellor’s Award for Academic Excellence (2000), and numerous undergraduate and post-graduate training scholarships. Due to work completed throughout her PhD, the Hon Roslyn Kelly (Chair of the National Breast Cancer Foundation Board of Trustees) nominated Dr Skelding for a Fresh Science Award in 2006, for which she was short-listed.

Dr Skelding's overarching research aim is tmprove patient outcomes and quality of life, by translating her research findings into the clinic.

Qualifications

  • PhD, University of Newcastle, 21/08/2008

Research

Research keywords

  • Cancer
  • Cell cycle
  • Leukaemia
  • Molecular Targeting
  • Protein Phosphorylation

Research expertise

Dr Skelding's research interests focus on examining signal transduction pathways and the role of targeting in regulating cancer cell proliferation, invasion/migration and chemotherapy resistance, so that new targets for controlling these cellular functions can be identified. Using a variety of molecular, biochemical and cellular techniques (including siRNA and overexpression transfection of cancer and normal cell lines, western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, proliferation assays, cell survival assays, flow cytometry, invasion and migration assays), she has identified new pathways involved in these processes. Additionally, she has developed novel inhibitors that can target these pathways. Dr Skelding is currently examining the efficacy of these new drugs in a range of cancer types, including acute myeloid leukaemia and childhood acute lymphoblastiac leukaemia.

Languages

  • English

Fields of Research

CodeDescriptionPercentage
111201Cancer Cell Biology50
111204Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)25
060103Cell Development, Proliferation And Death25

Memberships

Committee/Associations (relevant to research).

  • Member - Australian Neuroscience Society
  • Member - Australian Society of Biochemistry and Molecular Biology

Editorial Board.

  • Editor - Calcium Signalling

Invitations

Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253
APSN and JSN, Japan (Invited Presenter)
2012
Use of a common cold-producing virus as a potential treatment for breast cancer
NBCF, Australia (Invited Presenter)
2007
Importance of community support in performing medical research
NBCF, Australia (Invited Presenter)
2010

Collaboration

Dr Skelding's interest in the regulation of protein function via targeting has led to her forming local, national, and international collaborations to investigate the role of protein phosphorylation in heart disease and following stroke, as well as investigating protein phosphatase 2A (PP2A) reactivators as new treatments for leukaemia and breast cancer.

Administrative

Administrative expertise

Dr Skelding is a member of the University of Newcastle Faculty of Health Occupational Health and Safety Committee, and has been on the organising committee for several conferences and symposium days. Dr Skelding is also on the editorial board of the International Journal, Calcium Signalling.

Teaching

Teaching keywords

  • Anti-cancer drugs
  • Biochemistry
  • Enzymes
  • Genetics
  • Proteins
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapter (1 outputs)

YearCitationAltmetricsLink
2012Skelding KA, Rostas JA, 'The role of molecular regulation and targeting in regulating calcium/calmodulin stimulated protein kinases', Calcium Signaling, Springer New York LLC, New York, NY 703-730 (2012) [B1]

Co-authors: John Rostas

Journal article (14 outputs)

YearCitationAltmetricsLink
2014Skelding KA, Arellano JM, Powis DA, Rostas JA, 'Excitotoxic stimulation of brain microslices as an in vitro model of stroke.', J Vis Exp, e51291 (2014) [C1]
2014Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014)
2014Abdul Majeed ABB, Pearsall E, Carpenter H, Brzozowski J, Dickson PW, Rostas JAP, Skelding KA, 'CaMKII Kinase Activity, Targeting and Control of Cellular Functions: Effect of Single and Double Phosphorylation of CaMKIIa', Calcium Signaling, 1 36-51 (2014)
2012Skelding KA, Barry RD, Shafren DR, 'Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride', Investigational New Drugs, 30 568-581 (2012) [C1]

Co-authors: Darren Shafren

2012Skelding KA, Spratt NJ, Fluechter L, Dickson PW, Rostas JA, 'alpha CaMKII is differentially regulated in brain regions that exhibit differing sensitivities to ischemia and excitotoxicity', Journal of Cerebral Blood Flow and Metabolism, 32 2181-2192 (2012) [C1]
2012Majeed ABA, Rostas JAP, Carpenter H, Dickson PW, Skelding KA, 'Multi-site phosphorylation of CaMKII regulates CaMKII function co-operatively', JOURNAL OF NEUROCHEMISTRY, 123 116-116 (2012) [E3]
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
2011Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
2010Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
2009Skelding KA, Barry RD, Shafren DR, 'Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21', Breast Cancer Research and Treatment, 113 21-30 (2009) [C1]
2009Skelding KA, Rostas JA, 'Regulation of CaMKII in vivo: The importance of targeting and the intracellular microenvironment', Neurochemical Research, 34 1792-1804 (2009) [C1]
2006Skelding KA, Hickey DK, Horvat JC, Bao SS, Roberts KG, Read JM, et al., 'Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection', Vaccine, 24 355-366 (2006) [C1]
2004Hickey DK, Jones RC, Bao S, Blake AE, Skelding KA, Howland LJ, Beagley KW, 'Intranasal immunization with C.muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate', Vaccine, 22(31-32) 4306-4315 (2004) [C1]
2004Howland LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al., 'Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection', Infection and Immunity, 72 1019-1028 (2004) [C1]
Show 11 more

Review (1 outputs)

YearCitationAltmetricsLink
2014Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management (2014)

Conference (26 outputs)

YearCitationAltmetricsLink
2013Skelding KA, Majeed ABA, Carpenter H, Dickson PW, Rostas JA, 'Can functional outcomes of CaMKII double phosphorylation be predicted from outcomes following single phosphorylation of CaMKII?', JOURNAL OF NEUROCHEMISTRY, Cancun, MEXICO (2013) [E3]
2012Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is Differentially Regulated in Striatum and Cortex', JOURNAL OF NEUROCHEMISTRY (2012) [E3]
2012Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is differentially regulated in striatum and cortex', Journal of Molecular Neuroscience: Abstracts The 21st Annual Meeting of the Israel Society for Neuroscience & The First Binational Australian-Israeli Meeting in Neuroscience, Eilat, Israel (2012) [E3]
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
2012Abdul Majeed ABB, Skelding KA, Dickson PW, Rostas JA, 'Does phosphorylation of CaMKII at multiple sites regulate CaMKII targeting co-operatively or independently?', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
2012Skelding KA, Abdul Majeed ABB, Dickson PW, Spratt NJ, Rostas JA, 'CAMKII is regulated differently in brains regions with differing sensitivities to ischaemia/excitotoxicity', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
2011Skelding KA, Chung S, Pepperall D-G, Tomkins AJ, Spratt NJ, Rostas JA, 'The role of CaMKII in neuronal sensitivity to ischaemia', Oral abstracts. Australian Neuroscience Society Annual Meeting, Auckland, NZ (2011) [E3]
2010Rostas JA, Skelding KA, 'The role of targeting in the regulation of CaMKII in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology Symposium Abstracts, Melbourne, Vic (2010) [E3]

Co-authors: John Rostas

2010Skelding KA, Tomkins AJ, Fluechter L, Pepperall D-G, Spratt NJ, Rostas JA, 'Ischaemia-induced CaMKII phosphorylation in hypertensive and normotensive rats', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
2010Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
2010Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
2009Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, Busan, Korea (2009) [E3]
2009Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, Busan, Korea (2009) [E3]
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, Shanghai, China (2008) [E3]
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
2007Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
2006Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
2005Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
2005Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Combined transcutaneous and intranasal immunisation protects against genital tract Chlamydial infection', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts, USA. (2005) [E3]
2005Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
2005Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Comparison of intranasal and transcutaneous immunisation for the protection against Chlamydial pneumonia', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts (2005) [E3]
2004Skelding KA, Haley ES, Shafren DR, Barry RD, 'Viral oncolysis of human breast cancer', The Hunter Medical Research Institute Inaugural Cancer Conference, - (2004) [E3]

Co-authors: Darren Shafren

2004Beagley KW, Skelding KA, Hickey DK, Roberts KG, Bao S, 'Combined transcutaneous and intranasal immunization protects against genital tract Chlamydia infection', American Journal of Reproductive Immunology, St Louis, Missouri (2004) [E3]
2003Berry L, Hickey DK, Skelding KA, Bao S, Hansbro PM, Beagley KW, 'Transcutaneous immunisation prevents Chlamydia muridarum genital tract infection', American Journal of Reproductive Immunology, - (2003) [E3]

Co-authors: Philip Hansbro

Show 23 more
Edit

Grants and Funding

Summary

Number of grants17
Total funding$873,166

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2014 (6 grants)

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$300,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Miss Danielle Bond
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$300,00020142016
GNo:G1400921

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia$200,000
Funding Body: Cancer Australia

Project Team
Doctor Kathryn Skelding
SchemeRole
Priority-driven Collaborative Cancer Research SchemeChief Investigator
Total AmountFunding StartFunding Finish
$200,00020142015
GNo:G1300551

Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells$37,500
Funding Body: Hunter Medical Research Institute

Project Team
Mr Joshua Brzozowski, Doctor Jude Weidenhofer, Doctor Kathryn Skelding
SchemeRole
Postgraduate Research ScholarshipInvestigator
Total AmountFunding StartFunding Finish
$37,50020142016
GNo:G1401405

Myr-C310: A new treatment for childhood leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301349

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Doctor Kathryn Skelding
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301439

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000
Funding Body: University of Newcastle

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020142014
GNo:G1301404

2013 (2 grants)

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020132013
GNo:G1301348

Ultra-Low Temperature Cryogenic Freezer$24,596
Funding Body: NHMRC (National Health & Medical Research Council)

2012 (3 grants)

Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$34,00020122012
GNo:G1100983

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
SchemeRole
Near Miss GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020122012
GNo:G1200679

The 11th Biennial meeting of the Asian Pacific Society for Neurochemistry and the 55th Annual meeting of the Japanese Society for Neurochemistry, Kobe Conference Centre, 30 September - 2 October 2012$1,570
Funding Body: University of Newcastle - Faculty of Health and Medicine

Project Team
Doctor Kathryn Skelding
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,57020122012
GNo:G1201010

2011 (3 grants)

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
SchemeRole
Breast Cancer Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$35,00020112011
GNo:G1001005

Role of CaMKII targeting in stroke susceptibility and outcome$18,200
Funding Body: Hunter Medical Research Institute

Project Team
Emeritus Professor John Rostas, Doctor Neil Spratt, Doctor Kathryn Skelding
SchemeRole
Stroke Research Project GrantInvestigator
Total AmountFunding StartFunding Finish
$18,20020112011
GNo:G1001013

IMPLEN NanoPhotometer pearl$10,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Associate Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Doctor Frederick Walker, Doctor Rick Thorne, Doctor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Holt, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Mr Dan Johnstone, Ms Belinda Goldie, Ms Natalie Beveridge
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$10,00020112011
GNo:G1100030

2010 (1 grants)

ABI 7500 Real Time PCR System $34,000
Funding Body: NHMRC (National Health & Medical Research Council)

2009 (1 grants)

The 22nd Biennial Meeting of the ISN/APSN Joint Meeting, Busan South Korea, 23-28 August 2009$1,700
Funding Body: University of Newcastle - Faculty of Health and Medicine

Project Team
Doctor Kathryn Skelding
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,70020092009
GNo:G0190587

2005 (1 grants)

Viral Oncolysis of Human Breast Cancer$61,600
Funding Body: National Breast Cancer Foundation

Project Team
Doctor Kathryn Skelding
SchemeRole
Postgraduate Research ScholarshipChief Investigator
Total AmountFunding StartFunding Finish
$61,60020052005
GNo:G0184441
Edit

Research Supervision

Number of current supervisions2
Total current UoN PhD EFTSL0.8

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20142018PhD (Medical Biochemistry)Co-SupervisorIdentification of Biomarkers and Novel Targets for Prostate Cancer from Exosomes
20142018PhD (Medical Biochemistry)Co-SupervisorDeveloping Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells

Past Supervision

YearProgramSupervisor TypeResearch Title
2013M Philosophy (Medical Biochem)Co-SupervisorEffects of Multi-site Phosphorylation on CaMKII Function
Edit

Dr Kathryn Skelding

Work Phone(02) 4921 5982
Fax(02) 4921 6903
Email
PositionLecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle, Australia
Focus AreaMedical Biochemistry
Office
LS3-41,
Life Sciences,
Callaghan
University Drive
Callaghan NSW 2308
Australia
URL:www.newcastle.edu.au/profile/kathryn-skelding